Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Int J Exp Pathol ; 101(1-2): 55-64, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32459025

RESUMEN

Rheumatoid arthritis is a disabling autoimmune disease with a high global prevalence. Treatment with disease-modifying anti-arthritic drugs (DIMARDs) has been routinely used with beneficial effects but with adverse long-term consequences; novel targeted biologics and small-molecule inhibitors are promising options. In this study, we investigated whether purified omega unsaturated fatty acids (ω-UFAs) and dialysable leukocyte extracts (DLEs) prevented the development of arthritis in a model of collagen-induced arthritis (CIA) in mice. We also investigated whether the transcription factor NF-κB and the NLRP3 inflammasome were involved in the process and whether their activity was modulated by treatment. The development of arthritis was evaluated for 84 days following treatment with nothing, dexamethasone, DLEs, docosahexaenoic acid, arachidonic acid, and oleic acid. Progression of CIA was monitored by evaluating clinical manifestations, inflammatory changes, and histological alterations in the pads' articular tissues. Both DLEs and ω-UFAs led to an almost complete inhibition of the inflammatory histopathology of CIA and this was concomitant with the inhibition of NF-kB and the inhibition of the activation of NLRP3. These data suggest that ω-UFAs and DLEs might have NF-κB as a common target and that they might be used as ancillary medicines in the treatment of arthritis.


Asunto(s)
Antiinflamatorios/farmacología , Antirreumáticos/farmacología , Artritis Experimental/prevención & control , Cartílago Articular/efectos de los fármacos , Extractos Celulares/farmacología , Ácidos Grasos Insaturados/farmacología , Leucocitos , Animales , Ácido Araquidónico/farmacología , Artritis Experimental/inducido químicamente , Artritis Experimental/metabolismo , Artritis Experimental/patología , Cartílago Articular/metabolismo , Cartílago Articular/patología , Colágeno Tipo II , Diálisis , Ácidos Docosahexaenoicos/farmacología , Femenino , Inflamasomas/efectos de los fármacos , Inflamasomas/metabolismo , Ratones Endogámicos BALB C , Ratones Endogámicos DBA , FN-kappa B/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Ácido Oléico/farmacología
2.
Vet Immunol Immunopathol ; 264: 110647, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37672843

RESUMEN

Non-Hodkin's lymphoma (NHL) is the most frequent hematologic malignancy in humans and dogs. NKG2D is one of the most critical receptors on NK cells, recognizing their natural ligands on malignant cells such as A and B major histocompatibility complex-related proteins (MIC-A and MIC-B). Soluble molecules (sMIC-A and sMIC-B) can interfere with immune synapsis between NK cells and tumor cells, impeding NK cytotoxicity. The main objectives of this study were to analyze, in dogs with diffuse large B cell lymphoma, NK cell lymphoma, and reactive lymphadenopathies, the role of NK cells, their activating receptors NKG2D and NKp46, and their ligands MIC-A and MIC-B, as well as soluble molecules sMIC-A and sMIC-B. Thirty-six dogs with a possible diagnosis of NHL and eight healthy dogs were studied. NHL was diagnosed in 28 (78 %) dogs; in the other 8 (22 %), reactive lymphadenopathies were present. Most of the lymphomas corresponded to B cell NHL (82 %). The most predominant subtype was diffuse large B cell lymphoma (21, 71.5 %), followed by five cases (18 %) that were Non-B Non-T lymphomas (presumably NK cell lymphomas) and other B cell lymphomas (3, 10.5%). There were no cases of T cell NHL. MIC-A was positive in 7 of 27 (26 %) cases of NHL, and MIC-B in 20 of 27 (74 %) NHL. In non-malignant lymphadenopathies, three (37.5 %) dogs were positive for MIC-A, and five (62.5 %) expressed MIC-B. Dogs with lymphoma had higher numbers of NK cells than eight healthy dogs. In 15 dogs (12 cases with NHL and three cases with reactive adenopathies) and eight controls, there were no differences in the number of NK cells expressing NKP46 and NKG2D. NHL dogs had higher values of sMIC-A and sMIC-B. B-cell and NK cell lymphomas correspond to 86 % and 14 % of all canine lymphomas. MIC-A, MIC-B, and sMIC-A and sMIC-B were increased in canine lymphomas.


Asunto(s)
Enfermedades de los Perros , Linfadenopatía , Linfoma de Células B Grandes Difuso , Animales , Perros , Enfermedades de los Perros/metabolismo , Células Asesinas Naturales , Linfadenopatía/metabolismo , Linfadenopatía/veterinaria , Linfoma de Células B Grandes Difuso/veterinaria , Linfoma de Células B Grandes Difuso/metabolismo , Subfamilia K de Receptores Similares a Lectina de Células NK/metabolismo
3.
Rev Med Inst Mex Seguro Soc ; 50(3): 319-25, 2012.
Artículo en Español | MEDLINE | ID: mdl-23182263

RESUMEN

Lymphangioleiomyomatosis (LAM) is a rare lung disease of unknown etiology, described since 1918 associated with tuberous sclerosis complex (TSC-LAM) and are reported sporadically (S-LAM). It is classified within the group of interstitial lung diseases (ILD) and currently the European Respiratory Society (ERS) has published guidelines for diagnosis and treatment. The objective is to evaluate the clinical presentation of two patients, evolution, management, and review of current treatment. Both patients admitted in our hospital for examination, presenting with spontaneous pneumothorax. Their CT scan shows characteristic cystic lesions and thoracotomy with lung biopsy was performed because lack of expansion and to confirming the diagnosis. Despite the controversy about the optimal management of these patients, there is evidence about the use of progesterone routinely in patients with rapid deterioration of respiratory function when it was provided for a period of at least 12 months. Due to the rareness of the disease, it requires a patient registry to evaluate the use of experimental drugs or include them in research protocols to improve their prognosis.


Asunto(s)
Linfangioleiomiomatosis/diagnóstico , Adulto , Femenino , Humanos
4.
Cir Cir ; 87(S1): 8-16, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31501623

RESUMEN

BACKGROUND: Procedures to remove adiposities and skin, such as dermolipectomy, can develop wounds that are difficult to heal by conventional therapies. Mesenchymal stem cells are indicated as potential candidates for regenerative therapy in wounds, due to their multipotentiality, low immunogenicity, modulating capacity of inflammation and tissue modeling processes. CASE REPORT: Patient with dehiscent chronic ulcer secondary to dermolipectomy, who received cutaneous treatment with mesenchymal stem cells. The therapy induced scar formation and neovascularization, as well as the decrease of infiltrated leukocytes and proinflammatory cytokines. Mesenchymal cells are proposed as an interesting alternative for the treatment of postoperative lesions.


INTRODUCCIÓN: Los procedimientos para retirar adiposidades y piel, como la dermolipectomía, pueden desarrollar heridas difíciles de sanar mediante tratamientos convencionales. Se ha señalado que es posible utilizar las células madre mesenquimales en el tratamiento regenerativo en heridas, en virtud de su multipotencialidad, baja inmunogenicidad, capacidad moduladora de inflamación y procesos modeladores de tejidos. CASO CLÍNICO: Paciente con dehiscencia en úlcera crónica secundaria a dermolipectomía, sometida a tratamiento cutáneo con células madre mesenquimales. Se indujo formación de cicatriz y neovascularización, así como la disminución de leucocitos infiltrados y citocinas proinflamatorias. Se propone a las células mesenquimales como una alternativa interesante para el tratamiento de lesiones postoperatorias.


Asunto(s)
Contorneado Corporal/efectos adversos , Lipectomía/efectos adversos , Trasplante de Células Madre Mesenquimatosas , Medicina Regenerativa/métodos , Úlcera Cutánea/terapia , Dehiscencia de la Herida Operatoria/terapia , Gelatina de Wharton/citología , Adipogénesis , Adulto , Antígenos de Superficie/biosíntesis , Antígenos de Superficie/genética , Separación Celular , Enfermedad Crónica , Cicatriz/etiología , Femenino , Expresión Génica , Humanos , Inflamación , Células Madre Mesenquimatosas , Neovascularización Fisiológica , Osteogénesis , Úlcera Cutánea/etiología , Dehiscencia de la Herida Operatoria/etiología , Cicatrización de Heridas
5.
Acta Histochem ; 121(6): 680-689, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31213291

RESUMEN

Despite the success for the treatment of melanoma such as targeted molecular therapy, the use of such treatments are expensive For this reason, this study was carried out to explore the anti-cancer properties of available drugs that are able to modify the melanoma prognosis. The study was conducted in two phases: Evaluation of pharmacological effects of pentoxifylline (PTX) administered above (60 mg/kg) which is the therapeutic dose that is aimed at reducing the side-effect of radiotherapy, and of α- galactosylceramide (GalCer) administered at 100 µg/kg, as well as their combination using a murine model (BDF1 mice) of melanoma cell line (B16-F1, ATCC). For the radiotherapy phase, 9 Gy was applied in the tumor area, before (3 days), during (30 min) and after (3 days) the PTX + GalCer treatment. In both study phases, the mitosis rate, leukocyte infiltration and necro-apoptosis were assessed using histological and immunohistochemical approach and tumor volume evaluation as biomarkers. All treatments showed good prognosis results estimated as reduction of mitosis rate (PTX + GalCer after radiotherapy and GalCer), increased leukocyte infiltrate (PTX + GalCer after radiotherapy and GalCer) and necro-apoptosis augmentation (PTX + GalCer after radiotherapy and radiotherapy control). Nevertheless, a lower development of tumor volume was found in GalCer treatment. In this way, it is possible to suggest that the integrated treatment with immuno-stimulators such as GalCer, plus drug used for peripheral vascular disease (PTX) after radiotherapy is probably an alternative for controlling aggressive melanoma in murine model.


Asunto(s)
Apoptosis , Quimioradioterapia , Galactosilceramidas/farmacología , Leucocitos , Melanoma Experimental , Mitosis , Pentoxifilina/farmacología , Animales , Apoptosis/efectos de los fármacos , Apoptosis/efectos de la radiación , Línea Celular Tumoral , Leucocitos/metabolismo , Leucocitos/patología , Masculino , Melanoma Experimental/metabolismo , Melanoma Experimental/patología , Melanoma Experimental/terapia , Ratones , Mitosis/efectos de los fármacos , Mitosis/efectos de la radiación
6.
Cir Cir ; 82(1): 11-9, 2014.
Artículo en Español | MEDLINE | ID: mdl-25510787

RESUMEN

BACKGROUND: The diabetic cardiomyopathy occurs in both type 1 and type 2 diabetes mellitus. Hyperglycemia and associated metabolic changes participate in the pathogenesis of this disease. OBJECTIVE: To characterizes various pathological changes occurring during the development of diabetic cardiomyopathy in rats. METHODS: Diabetic rats were used for streptozotocin administration. At 7, 14, 21 and 30 days after toxic administration, the heart was obtained and placed in a Hartman solution and 4% p-formaldehyde. Five-micrometer thick sections were stained with hematoxylin-eosin, Masson trichrome and immunocytochemistry using anti-ß-tubulin antibody. RESULTS: At 14 days after application of streptozotocin, dilated sinusoids with endothelial lining in the myocardium and collagen deposits in the cardiac interstitium and between the Purkinje fibers were observed. At 21 days there was a slight decrease of the arteriolar lumen due to hyperplasia of the medial layer. It is important to note that cardiac sinusoids as well as collagen deposits became more evident at 30 day of the study, as well as a major derangement of the microtubular system of the cardiomyocytes. CONCLUSIONS: Cardiac sinusoids representing fetal vascular pattern and interstitial fibrosis in the myocardium and the microtubular derangement of cardiomyocytes support the fact that the pathophysiological mechanism of diabetic cardiomyopathy begins in the coronary microcirculation due to changes in cardiac metabolism, contributing to the development of myocardial dysfunction in diabetes.


Antecedentes: la miocardiopatía diabética ocurre en ambos tipos de diabetes mellitus y en su patogenia intervienen la hiperglucemia y los cambios metabólicos asociados. Objetivo: caracterizar los diferentes cambios patológicos que aparecen durante la evolución de la miocardiopatía diabética en la rata. Material y métodos: estudio transversal comparativo en dos grupos de ratas diabéticas por la administración de estreptozotocina. A los 14, 21 y 30 días de la administración del tóxico se obtuvieron los corazones, que se colocaron en p-formaldehído al 4%. Se efectuaron cortes de 5 µm y se tiñeron con hematoxilina-eosina, tricrómica de Masson e inmunocitoquímica con anticuerpos anti ß-tubulina. Resultados: a los 14 días de la aplicación de la estreptozotocina se observaron en el miocardio sinusoides dilatadas y depósito de colágena entre las fibras de Purkinje e intersticio cardiaco. A los 21 días disminuyó la luz arteriolar por hiperplasia de la capa media. A los 30 días del estudio se hicieron más evidentes los sinusoides cardiacos y los depósitos de colágena y un importante desarreglo del sistema microtubular de los cardiomiocitos. Conclusiones: los sinusoides cardiacos, que representan un patrón vascular fetal y la fibrosis intersticial en el miocardio y el desarreglo microtubular de los cardiomiocitos, apoyan el hecho de que el mecanismo fisiopatológico de la miocardiopatía diabética se inicia en la microcirculación coronaria debido a cambios en el metabolismo cardiaco que contribuyen a la disfunción miocárdica durante el estado diabético.


Asunto(s)
Cardiomiopatías/patología , Complicaciones de la Diabetes/patología , Diabetes Mellitus Experimental/patología , Animales , Glucemia/análisis , Peso Corporal , Capilares/patología , Cardiomiopatías/etiología , Colágeno/análisis , Circulación Coronaria , Citoesqueleto/ultraestructura , Angiopatías Diabéticas/patología , Ingestión de Alimentos , Fibrosis , Masculino , Microcirculación , Microtúbulos/ultraestructura , Miocitos Cardíacos/patología , Ratas , Ratas Wistar , Estreptozocina , Tubulina (Proteína)/análisis
7.
Arch. Inst. Cardiol. Méx ; 68(3): 232-8, mayo-jun 1998. ilus
Artículo en Español | LILACS | ID: lil-227567

RESUMEN

El fibroelastoma papilar en un tumor cardiaco benigno raro, que previo al advenimiento de la ecocardiografía, era diagnosticado sólo en necropsias o de manera incidental en cirugía. Se puede presentar en la fuperficie endocárdica o en cualquiera de las válvulas, y aunque su tañamo generalmente es pequeño, se le asocia a fenómenos embolígenos, dolor torácico y muerte súbita. En este reporte se presenta el primer caso de fibroelastoma papilar, en presencia de una prótesis valvular mecánica en posición mitral, en una paciente de 55 años con cardiopatía reumática inactiva. El tumor fue detectado mediante ecocardiografía transtorácica y transesofágica


Asunto(s)
Humanos , Femenino , Cardiopatía Reumática/terapia , Ecocardiografía , Enfermedades de las Válvulas Cardíacas/cirugía , Enfermedades de las Válvulas Cardíacas/patología , Enfermedades de las Válvulas Cardíacas/terapia , Enfermedades de las Válvulas Cardíacas , Fibroma , Fibroma/patología , Fibroma/cirugía , Neoplasias Cardíacas , Neoplasias Cardíacas/patología , Neoplasias Cardíacas/cirugía , Válvula Mitral , Marcapaso Artificial
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA